Medication-info.com Search Menu

Erwinase: Uses, Side Effects and Dosage

Updated:
Facts
Status:
Prescription (Rx)
Strength:
10000 IU/mL
Other brand names:
Active ingredient:

Patient information: uses, side effects, how to take - Erwinase

What is in this leaflet

  1. 1. What Erwinase is and what it is used for
  2. 2. What you need to know before you are given Erwinase.
  3. 3. How Erwinase is given
  4. 4. Possible side effects
  5. 5. How to store Erwinase
  6. 6. Contents of pack and other information

1. What Erwinase is and what it is used for

How does Erwinase work

Erwinase is an anti-blood-cell-cancer treatment from the pharmacotherapeutic group: Antineoplastic and immunomodulating agents. It works by lowering the levels of asparagine in your body, a substance the cancer cells need to survive.

What this medicine is used for

Erwinase is used for the treatment of a cancer of the white blood cells called Acute Lymphoblastic Leukaemia, in patients aged 4 months and above, who have developed allergic reactions to E.coli derived asparaginase.

Erwinase may be used alone or with other treatments.

2. What you need to know before you are given Erwinase

You should not be given Erwinase if:

  • you have previously had a severe allergic reaction to the active substance (Crisantapase- L- asparaginase from Erwinia chrysanthemi) or are allergic to any of the other ingredients of this medicine (see section 6).
  • You have, or have previously, had serious problems with your pancreas (severe pancreatitis) from using a medicine containing L-asparaginase
  • You have serious problems with your pancreas (severe pancreatitis)

Warnings and precautions

Talk to your doctor or pharmacist or nurse before taking Erwinase.

The following complications may arise during treatment with Erwinase:

  • Serious life threatening allergic reactions. The hospital will have the necessary precautions in place to deal with such situations.
  • Inflammation of the pancreas. If you experience abdominal pain this may be a sign of pancreatitis and should be reported to your doctor immediately. Fatal outcomes associated with pancreatitis have occurred.
  • Increases in your blood sugar levels (Hyperglycemia). This can be controlled by receiving insulin sometimes even to fatal amounts (Hyperglycemia). This can be controlled by receiving insulin.
  • Bleeding and blood clot disorders. During treatment your body’s ability to prevent excessive bleeding may be affected. In the case you experience any significant bleeding your treatment will be stopped. Your doctor will determine if, and when, treatment can be restarted.
  • Liver dysfunctions can be caused or worsened. Discontinuation of Erwinase will be considered in the event of a severe reaction. Treatment can be restarted under close monitoring, but only once at least near complete recovery is achieved.
  • Neurological disorders have been reported with fatal outcomes. Posterior reversible encephalopathy syndrome (characterised by headache, confusion, seizures and visual loss) may require blood- pressure lowering medicines and in case of seizure, anti-epileptic treatment.
  • Kidney impairment due to high levels of a substance called uric acid in your blood from the chemotherapy.
  • Reduced immune system that may increase your chances of an infection.

Monitoring during treatment with Erwinase

You will be monitored closely during and after treatment with Erwinase for:

  • Allergic reactions
  • Pancreas, kidney and liver functions
  • Normal blood content

For traceability purposes your health care professional will record the product name and batch number for each dose of Erwinase you receive.

Other medicines and Erwinase

Tell your doctor or your pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription, particularly any of the following:

  • Types of medicines used to treat cancer called ‘methotrexate’ or ‘cytarabine’ as they can affect the way Erwinase works.
  • Prednisone which is used in cancer treatment may increase the risk of a change in clotting.
  • Vincristine which is used in cancer treatment, this can increase the toxic effects of both medicinal products and increase the risk of anaphylaxis.
  • Oral contraceptives.

Your doctor or your nurse will not mix Erwinase with other medicines in the same infusion.

However you will probably be given other medicines before, during or after Erwinase treatment as part of your course of therapy.

Pregnancy

If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Breastfeeding

You must not breast-feed your baby during your treatment with Erwinase, there may be a risk to the feeding child.

Fertility & Family planning

Potential for a decrease in male fertility cannot be out ruled.

When appropriate both men and women should use necessary contraceptive measures before, and for at least three months after treatment with Erwinase. Women should use a form of contraception other than oral contraceptives.

Driving and using machines

Erwinase can cause dizziness and drowsiness. This can affect your coordination and therefore your ability to drive and operate machinery.

Erwinase contains sodium and glucose

Erwinase contains the following ingredients:

  • sodium (less than 23 mg per dose). You can consider this medicine as essentially sodium free if you are on a salt-free or low-salt diet.
  • glucose. If you are diabetic, please note that each bottle of Erwinase contains 5 mg glucose.

3. How Erwinase is given

Dosage

Erwinase will only be given to you by health care professionals who are experienced in giving chemotherapy.

Your doctor will decide what dose to administer, how often you will be given Erwinase and for how long. It varies according to your body weight, your specific condition being treated, and your response to therapy.

Method of administration

Erwinase can be given to you in one of the following ways:

  1. a) Into a vein (intravenous use). This may be given over 1 to 2 hours.
  2. b) Into a muscle (intramuscular use).

If you are given more Erwinase than you should

If you are concerned that you have been given too much Erwinase, contact your doctor or another healthcare professional immediately.

If you think you have missed a dose of Erwinase

If you are concerned that you have missed a dose, contact your doctor or another healthcare professional immediately.

If you have any further questions on this product, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all medicines, Erwinase can cause side effects, although not everybody gets them. Erwinase will be given under strict medical supervision and your doctor may give you other medicines to treat these side effects. Most of the side effects will stop once you stop taking Erwinase.

Serious side effects

Tell your doctor immediately if you experience:

  • Severe allergic reactions including blue discolouration of the lips and extremities (possible symptoms of hypoxia), swelling of the face and/or, shortness of breath, increased heart rate; wheezing, difficulty swallowing, hay fever like symptoms, rash, chills, flushing, high or low blood pressure, vomiting
  • Redness, pain, swelling, bruising, or hardening of the skin at the site of the injection
  • Damage to the Central Nervous System symptoms may include coma, encephalopathy, hallucinations, muscle weakness, confusion, dizziness, drowsiness, agitation, difficulty speaking
  • Arm, leg or calf pain with or without swelling (symptoms of blood clots in the arm or leg), abdominal pain (symptoms of a blood clot in the area of the stomach, intestines, and kidneys) chest pain spreading to the arms, neck, jaw, back or stomach, feeling sweaty and breathless (which may be symptoms of a heart attack/myocardial infarction)
  • Pain near your stomach or in your back (this may be inflammation of your pancreas)
  • High blood sugar levels (hyperglycemia)
  • Increased frequency of bleeding events including bruising even if you have not been injured
  • Changes in liver functions (identified by laboratory testing)

Other side effects

Talk to your doctor if you get any of the following:

Very common side effects (may affect more than 1 in 10 people):

  • Infections, including blood infections caused by bacteria (sepsis). This may be due to low levels of white cells in your blood. You may experience fever, a rapid heart rate, confusion or a rash.
  • Decreases in normal blood content. Some of which may be due to reduced bone marrow activity.
  • Increase in blood fats, bilirubin, creatinine, urea levels and certain liver enzymes- your doctor will monitor these.
  • Weight loss
  • Generalised pain/Muscle pains
  • Nausea

Common (may affect up to 1 in 10 people) side effects include:

  • Difficulty breathing or stopping breathing
  • Mucositis (inflammation of the digestive tract)
  • Diarrhoea
  • Abdominal pain/discomfort
  • tiredness or headache
  • High temperature

Uncommon (may affect up to 1 in 100 people) side effects include:

  • life threatening complications of uncontrolled diabetes
  • High blood levels of ammonia
  • Fits (convulsions)
  • Build up of fats in the liver
  • Kidney dysfunction

Rare (may affect up to 1 in 1,000 people) side effects include:

  • Posterior reversible encephalopathy syndrome (a condition characterised by headache, confusion, seizures and visual loss).

Not known (frequency cannot be estimated from the available data)

  • Inflammation of the salivary gland at the back of the throat
  • Liver failure, increased mass of liver, jaundice
  • Decreased albumin levels in the blood causing water retention
  • Blistering and peeling of the skin (Toxic epidermal necrolysis)
  • Joint pain

Additional side effects in children and adolescents

Liver, pancreas and blood clotting side effects may be higher in adults compared to children.

Reporting of side effects

If you get any side effects, talk to your doctor or,pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via MHRA Yellow Card in Google Play or Apple App Store.

By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Erwinase

Keep this medicine out of the sight and reach of children.

Erwinase will not be used after the expiry date printed on the label after “EXP”. The expiry date refers to the last day of the month.

The unopened Erwinase vials will be stored in a refrigerator (between +2°C to +8°C) by the hospital.

After reconstitution, the product should be used within 15 minutes. If the delay is more than 15 minutes, the solution should be withdrawn into a glass or polypropylene syringe and used within 8 hours. The reconstituted product should be stored below 25°C.

6. Contents of the pack and other information

What Erwinase contains

The active substance is crisantaspase (L-asparaginase from Erwinia chrysanthemi). Each vial contains 10,000 International units of cristanaspase (L-asparaginase from Erwinia chrysanthemi).

The other excipients are sodium chloride (See section 2) and glucose monohydrate (See section 2).

What Erwinase looks like and contents of the pack

Erwinase is provided as a powder for solution for injection/infusion

It comes as a white lyophilized powder in a clear glass bottle with a rubber stopper and an aluminium seal. Each pack contains 5 glass bottles of powder.

Marketing Authorisation Holder and Manufacturer

Porton Biopharma Limited, Manor Farm Road,

Porton Down, Salisbury, SP4 0JG United Kingdom

This leaflet was last revised in June 2020

Erwinase is a registered trademark of Porton Biopharma Limited.

About this document

Source: FDA drug labeling via NLM DailyMed · View the label on DailyMed

Revision date stated in the text: June 2020

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Erwinase

Rx or OTC
Prescription (Rx)?
  • This drug is available only with a prescription from a licensed healthcare provider.
  • Rx
Drug class Asparagine-specific Enzyme
Active ingredient Asparaginase erwinia chrysanthemi 10000 IU/mL
Dosage form Injection, powder, lyophilized, for solution
Route Intramuscular, Intravenous
Marketing status not in the current FDA NDC Directory
Company (applicant) Porton Biopharma Limited
FDA approval UNAPPROVED DRUG FOR USE IN DRUG SHORTAGE
Manufacturers 1 labelers list this drug on DailyMed
Packages (NDC)
Package
10000 IU/mL – 1 ml in 1 vial, glass / 5 in 1 carton NDC 81561-413-01

Source: FDA drug labeling via NLM DailyMed, data as of October 31, 2026. FDA data (DailyMed, Orange Book, Drug Shortages, enforcement reports). Not a substitute for the advice of a doctor or pharmacist.